CRANDELL KEITH — SEC insider filings

SEC reporting owner CIK 1219039. 90 insider filings on record with FilingPulse; latest filed 2026-11-05.

Transaction summary — filings shown

Covers the 50 most recent of 90 filings on record, filed 2022-06-06 to 2026-11-05. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Prime Medicine, Inc. (PRME)10% owner34 legs · 7,030,300 sh · $43,599,990—6
Metsera, Inc. (MTSR)Director, 10% owner22 legs · 2,222,222 sh · $39,999,996—9
Lyell Immunopharma, Inc. (LYEL)10% owner32 legs · 2,809,352 sh · $37,499,977——
Neumora Therapeutics, Inc. (NMRA)10% owner920 legs · 3,922,764 sh · $36,430,001—12
Kardigan, Inc. (KARD)Director, 10% owner21 leg · 1,250,000 sh · $20,000,000—4
Aspen Neuroscience, Inc. (ASPE)10% owner23 legs · 1,333,333 sh · $19,999,995—18
Seaport Therapeutics, Inc. (SPTX)10% owner11 leg · 1,100,000 sh · $19,800,000—4
Sana Biotechnology, Inc. (SANA)10% owner13 legs · 1,818,181 sh · $9,999,996——
Codiak BioSciences, Inc. (CDAK)10% owner11 leg · 5,000,000 sh · $7,500,000—1
Boundless Bio, Inc. (BOLD)10% owner22 legs · 200,000 sh · $3,200,0001 leg · 16,000 sh · $39,84012

+7 more issuers among the filings shown — every filing appears in the table below.

Insider filings — CRANDELL KEITH

FiledFormIssuerReported transactionsSource
2026-11-054Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, GILLIS STEVEN, NELSEN ROBERT, Burow Kristina, BERNS PAUL L, BYBEE CLINTON
Purchase (P): 2,321,262 @ $10.77EDGAR
2026-11-024Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 66,666 @ $15 · Conversion (C): 187,182 · Conversion (C): 298,258 · Conversion (C): 286,304 · Conversion (C): 295,490 · Conversion (C): 259,948 · +15 moreEDGAR
2026-10-293Aspen Neuroscience, Inc. (ASPE)
jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners X, LLC, Burow Kristina, GILLIS STEVEN, NELSEN ROBERT
Holdings only — no transactions reportedEDGAR
2026-10-194CITY THERAPEUTICS, INC. (CTY)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., Burow Kristina, GILLIS STEVEN
Conversion (C): 3,294,900 · Conversion (C): 5,482,309 · Conversion (C): 2,027,006 · Purchase (P): 170,000 @ $18 · Conversion (C): 3,000,000 (derivative) @ $0 · Conversion (C): 4,991,633 (derivative) @ $0 · +1 moreEDGAR
2026-10-153CITY THERAPEUTICS, INC. (CTY)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., Burow Kristina, GILLIS STEVEN
Holdings only — no transactions reportedEDGAR
2026-07-064Boundless Bio, Inc. (BOLD)
jointly with BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN, Burow Kristina
Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0EDGAR
2026-06-244Kardigan, Inc. (KARD)
jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Purchase (P): 1,250,000 @ $16EDGAR
2026-06-224Kardigan, Inc. (KARD)
jointly with ARCH Venture Partners XIII, LLC, ARCH Venture Partners XIII, L.P., ARCH Venture Fund XIII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 13,792,035 · Conversion (C): 5,148,587 (derivative) · Conversion (C): 1,204,000 (derivative) · Conversion (C): 2,306,401 (derivative)EDGAR
2026-06-124908 Devices Inc. (MASS)Option exercise (M): 14,083 · Option exercise (M): 14,083 (derivative) @ $0 · Grant/award (A): 13,656 (derivative) @ $0 · Grant/award (A): 6,209 (derivative) @ $0EDGAR
2026-05-044Seaport Therapeutics, Inc. (SPTX)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 2,513,686 · Conversion (C): 2,681,265 · Purchase (P): 1,100,000 @ $18 · Conversion (C): 2,513,686 (derivative) @ $0 · Conversion (C): 2,681,265 (derivative) @ $0EDGAR
2026-03-094Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, NELSEN ROBERT, Burow Kristina, GILLIS STEVEN, BERNS PAUL L, BYBEE CLINTON
Purchase (P): 488,090 @ $25.61EDGAR
2026-02-094Twist Bioscience Corp (TWST)Grant/award (A): 5,095 @ $0EDGAR
2025-11-144Metsera, Inc. (MTSR)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, GILLIS STEVEN, NELSEN ROBERT
Disposition to issuer (D): 18,503,128 · Disposition to issuer (D): 8,313,680EDGAR
2025-10-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON
Purchase (P): 1,915,700 @ $2.61EDGAR
2025-08-014Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., Burow Kristina, GILLIS STEVEN
Purchase (P): 3,030,300 @ $3.30EDGAR
2025-07-294Lyell Immunopharma, Inc. (LYEL)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON, NELSEN ROBERT
Holdings only — no transactions reportedEDGAR
2025-06-134908 Devices Inc. (MASS)Option exercise (M): 11,364 · Option exercise (M): 11,364 (derivative) @ $0 · Grant/award (A): 14,083 (derivative) @ $0 · Grant/award (A): 6,516 (derivative) @ $0EDGAR
2025-02-074Twist Bioscience Corp (TWST)Grant/award (A): 4,472 @ $0EDGAR
2025-02-034Metsera, Inc. (MTSR)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Fund XII, L.P., ARCH Venture Partners XII, L.P., ARCH Venture Fund XIII, L.P., ARCH Venture Partners XIII, L.P., ARCH Venture Partners XIII, LLC, GILLIS STEVEN, NELSEN ROBERT
Conversion (C): 16,006,949 · Conversion (C): 7,523,682 · Purchase (P): 1,432,224 @ $18 · Purchase (P): 789,998 @ $18 · Conversion (C): 19,933,333 (derivative) · Conversion (C): 15,000,000 (derivative) · +3 moreEDGAR
2024-06-144908 Devices Inc. (MASS)Option exercise (M): 7,777 · Option exercise (M): 7,777 (derivative) @ $0 · Grant/award (A): 11,364 (derivative) @ $0 · Grant/award (A): 15,996 (derivative) @ $0EDGAR
2024-06-104Rapport Therapeutics, Inc. (RAPP)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., NELSEN ROBERT, Burow Kristina, GILLIS STEVEN
Conversion (C): 3,728,738 @ $0 · Conversion (C): 20,000,000 (derivative) @ $0 · Conversion (C): 11,924,138 (derivative) @ $0EDGAR
2024-04-044Boundless Bio, Inc. (BOLD)
jointly with BYBEE CLINTON, NELSEN ROBERT, GILLIS STEVEN
Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 moreEDGAR
2024-02-204Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., Burow Kristina, GILLIS STEVEN
Purchase (P): 3,200,000 @ $6.25EDGAR
2024-02-124Sana Biotechnology, Inc. (SANA)
jointly with BYBEE CLINTON, Burow Kristina, GILLIS STEVEN
Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50EDGAR
2024-02-094Twist Bioscience Corp (TWST)Grant/award (A): 5,815 @ $0EDGAR
2023-12-124Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON
Other (J): 703,061 · Other (J): 1,176,593EDGAR
2023-11-154Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 31,653 @ $11.75 · Purchase (P): 3,357 @ $11.98EDGAR
2023-11-134Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 69,127 @ $10.78 · Purchase (P): 23,124 @ $11.79 · Purchase (P): 31,079 @ $10.53 · Purchase (P): 11,844 @ $11.37 · Purchase (P): 5,431 @ $11.75EDGAR
2023-11-074Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 22,420 @ $11.38 · Purchase (P): 43,082 @ $11.55 · Purchase (P): 30,192 @ $11.50EDGAR
2023-09-294Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 16,841 @ $13.06 · Purchase (P): 25,110 @ $13.69 · Purchase (P): 34,560 @ $13.98EDGAR
2023-09-274Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 34,000 @ $11.73 · Purchase (P): 24,504 @ $12.31EDGAR
2023-09-254Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT
Purchase (P): 40,000 @ $11.14 · Purchase (P): 30,773 @ $10.80 · Purchase (P): 29,967 @ $11.65EDGAR
2023-09-204Neumora Therapeutics, Inc. (NMRA)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners XII, LLC, ARCH Venture Partners XII, L.P., ARCH Venture Fund XII, L.P., GILLIS STEVEN, NELSEN ROBERT, BYBEE CLINTON
Conversion (C): 684,167 · Conversion (C): 1,144,973 · Conversion (C): 6,895,021 · Conversion (C): 6,576,400 · Conversion (C): 2,124,143 · Purchase (P): 1,500,000 @ $17 · +5 moreEDGAR
2023-08-104DA32 Life Science Tech Acquisition Corp. (DALS)Other (J): 1,600,000EDGAR
2023-06-164908 Devices Inc. (MASS)Option exercise (M): 4,771 · Option exercise (M): 4,771 (derivative) @ $0 · Grant/award (A): 7,777 (derivative) @ $0 · Grant/award (A): 12,076 (derivative) @ $0EDGAR
2023-04-044Quanterix Corp (QTRX)Grant/award (A): 1,170 @ $11.16EDGAR
2023-02-094Twist Bioscience Corp (TWST)Grant/award (A): 8,212 @ $0EDGAR
2023-01-044Quanterix Corp (QTRX)Grant/award (A): 8,083 @ $0 · Grant/award (A): 1,015 @ $12.86 · Grant/award (A): 12,124 (derivative) @ $0EDGAR
2022-10-264Prime Medicine, Inc. (PRME)
jointly with ARCH Venture Partners X, LLC, ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., Burow Kristina, GILLIS STEVEN
Conversion (C): 5,728,297 · Conversion (C): 5,728,297 · Purchase (P): 400,000 @ $17 · Purchase (P): 400,000 @ $17 · Conversion (C): 16,666,667 (derivative) @ $0 · Conversion (C): 16,666,664 (derivative) @ $0 · +2 moreEDGAR
2022-10-054Quanterix Corp (QTRX)Grant/award (A): 1,326 @ $10.48EDGAR
2022-09-154Codiak BioSciences, Inc. (CDAK)
jointly with ARCH Venture Fund VIII, L.P., ARCH Venture Fund VIII Overage, L.P., BYBEE CLINTON, NELSEN ROBERT, ARCH Venture Partners VIII, LLC, ARCH Venture Partners VIII, L.P.
Purchase (P): 5,000,000 @ $1.50 · Purchase (P): 5,000,000 (derivative)EDGAR
2022-09-074Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 196,003 @ $0 · Other (J): 253,997 @ $0 · Other (J): 11,763 @ $0 · Other (J): 1,338 @ $0 · Other (J): 2,662 @ $0 · Other (J): 239,559 @ $0 · +4 moreEDGAR
2022-09-014Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 · Other (J): 217,781 @ $0 · +4 moreEDGAR
2022-08-264Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 · Other (J): 217,781 @ $0 · +4 moreEDGAR
2022-08-224Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0EDGAR
2022-08-164Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0 · Other (J): 217,781 @ $0 · +9 moreEDGAR
2022-07-064Quanterix Corp (QTRX)Grant/award (A): 893 @ $16.79EDGAR
2022-06-174908 Devices Inc. (MASS)Option exercise (M): 1,379 · Option exercise (M): 1,379 (derivative) @ $0 · Grant/award (A): 4,771 (derivative) @ $0 · Grant/award (A): 7,970 (derivative) @ $0EDGAR
2022-06-104Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 1,475 @ $0 · Other (J): 2,952 @ $0EDGAR
2022-06-064Vir Biotechnology, Inc. (VIR)
jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX, L.P., ARCH Venture Fund IX Overage, L.P., BYBEE CLINTON
Other (J): 217,781 @ $0 · Other (J): 282,219 @ $0 · Other (J): 13,076 @ $0 · Other (J): 4,426 @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1219039 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs